Opdivo (nivolumab)

pCPA File Number: 23122

Negotiation Status:

Concluded with an LOI

Indication(s):

With doxorubicin, vinblastine and dacarbazine (AVD) in previously untreated stage III or IV Hodgkin Lymphoma.

Sponsor/Manufacturer:

Bristol Myers Squibb Canada Inc.

CDA-AMC Project Number:

PX0376-000

pCPA Engagement Letter Issued:

2025-08-13

Negotiation Process Concluded:

2025-09-04